Global Biosimilars Market-Growth, Trends & Forecasts (2017 - 2022)

The Global Biosimilars Market was valued at USD 5237.0 currently and is projected to reach USD 28200.0 million by 2020, at a CAGR of 40.3% during the forecast period from 2015 to 2021.

The global biosimilars market is segmented on the basis of technology, product, application, service, and geography. The technology segment is further divided into Monoclonal Antibody Technology and Recombinant DNA Technology; the product segment into Peptides, Recombinant Non-Glycosylated Proteins and Recombinant Glycosylated Proteins; the application segment into Growth Hormone Deficiency, Oncology Diseases, Autoimmune disorders, Blood Disorders; and the Services segment into Contract Manufacturing Organizations, Contract Research Organizations and Academia. On the basis of geography, the report has been segmented into North America (U.S., Canada, Mexico), Europe (U.K, Germany, France, Italy, Spain) , Asia-Pacific (India, China, Japan, Australia), and the Rest of the World.

The factors that are contributing to the growth of this market are the intended reductions in the healthcare expenditure, cost-effectiveness of biosimilar drugs, and the increasing number of off-patented drugs whose total sales in the year 2013 was USD 9.1 billion will expire in 2018 and 2016 in the EU and the US, respectively. Similarly, six such multi-billion drugs will expire in coming five years. Other than these, the rising demand for biosimilars is also another driving force for the biosimilars market.

However, there are factors that are restraining the growth of this market, such as the different regulatory frameworks and requirements in different countries and high manufacturing complexities, since the manufacturing of biosimilars requires sophisticated technologies. Although, small scale production is quite possible, but there is a risk involved in the scaling-up of the production. This brings forward the concern of operating on a large scale.

The major players of this market are Sandoz, Dr. Reddys, Teva Pharmaceuticals, Hospira, Bioton, Biocon, Sun-Ranbaxy, Zydus Cadila, Synthon, and Celltrion. This report offers comprehensive profiles of these companies composed of their business strategy for biosimilars.

Key Deliverables in the Report:

Global, regional and country-level analysis along with forecasts of the study market

Study of the effect of exogenous & endogenous factors, viz. demographic, economics, and political factors, among others, which affect the global market

Porterfive forces framework incorporating the factors influencing each force to determine the intensity of competition

Segment and sub-segment level analysis of the market over the review and forecast period

Identification of key factors instrumental in changing the market scenario, exploiting new opportunities and gaining competitive edge

SWOT analysis for key players and a detailed study of their current strategic interests and key financial performance indicators

1. Introduction

1.1 Report Description

1.2 Research Methodology

2. Executive Summary

3. Market Overview

3.1 Market Definition

3.2 Market Drivers

3.2.1 Reductions healthcare expenditure

3.2.2 Cost-effectiveness

3.2.3 Increasing number of off-patented drugs

3.2.4 Rising demand for biosimilars

3.3 Market Restraints

3.3.1 Different regulatory frameworks and requirements in countries

3.3.2 High manufacturing complexities

3.4 Market Opportunitites

4. Porters Five Force Analysis

4.1 Bargaining Power of suppliers

4.2 Bargaining power of buyers

4.3 Degree of competition

4.4 Threat of substitution

4.5 Threat of new entrants

5. Market Segmentation

6. Biosimilars Market

6.1 Biosimilars Market

6.1.1 by Technology Monoclonal Antibody Technology Recombinant DNA Technology

6.1.2 By Product Peptides Recombinant Non-Glycosylated Proteins Recombinant Glycosylated Proteins

6.1.3 By Applications Growth Hormone Deficiency Oncology Diseases Autoimmune disorders Blood Disorders

6.1.4 By Services Contract Manufacturing Organizations Contract Research Organizations Academia

6.1.5 By Geography North America USA Canada Mexico Europe UK Germany France Italy Spain Asia Pacific China Japan India Australia ROW

7. Competitive Landscape

7.1 Mergers & Acquisitions

7.2 Agreements, Collaborations & Partnerships

7.3 New Product Launches

7.4 Recommendations to new market players

8. Company Profiles

8.1 Cipla

8.2 Dr Reddys

8.3 Teva pharmaceuticals


8.5 Hospira

8.6 Wockhardt

8.7 Bioton

8.8 Biocon

8.9 Sun-Ranbaxy

8.10 Reliance Life Sciences

8.11 Lg Life Sciences

8.12 3SBio

8.13 Zydus Cadila

8.14 Actavis

8.15 Synthon

8.16 Celltrion

8.17 Mylan

8.18 Roche

8.19 Shanghai Fosun

8.20 Biosidus

8.21 Amgen

Content are not available

Choose License Type